Telling Fred 4/A

What Happened

• Fred Telling, a director of Oragenics, was granted options covering 125,000 shares on 2025-12-11 (reported as a derivative award) and sold 210 common shares in an open‑market transaction on 2025-12-12 for a total of about $198.
• The grant is an award of options under the company's 2021 Equity Incentive Plan (non‑employee director compensation). The options vest immediately; the exercise price is the company's closing price on the grant date. The sale was a small, routine disposition.

Key Details

• Transactions and dates:
  • 2025-12-11: Grant/award of options to acquire 125,000 shares (derivative award; reported value $0).
  • 2025-12-12: Open market sale of 210 shares at a weighted average price reported as $0.94, total ≈ $198.
• Sale price details: weighted average sale price ranged from $0.9440 to $0.9451 (reporting person offered to provide breakdown on request).
• Amended filing: This Form 4 is an amendment to correct the amount of securities beneficially owned to reflect a 1‑for‑30 reverse stock split; the amendment updates the prior reporting of beneficial ownership.
• Shares owned after transaction: the amendment corrects beneficial ownership figures (see filing); the filing text does not provide a separate reconciled total in the summary text here.

Context

• The 125,000‑share item is an option award (derivative); the options vest immediately and have an exercise price equal to the company's closing price on the grant date. This is not an outright purchase of common stock.
• The 210‑share sale is very small (≈$198) and is typically considered routine—does not on its own indicate a change in insider sentiment. The amended filing is administrative, correcting ownership counts after a reverse split.